NEW YORK--(BUSINESS WIRE)--Cowen Group, Inc. (“Cowen”) (NASDAQ:COWN) today announced that Boris Peaker has joined Cowen and Company’s Equity Research department as a Managing Director to cover Biotechnology stocks. Mr. Peaker is based in New York and reports to Robert Fagin, Cowen’s Director of Research.
“We’re thrilled to welcome Boris back to Cowen, where he began his equity research career,” said Mr. Fagin. “We look forward to adding Boris’ insightful research product to our already preeminent biotech platform, and to his collaboration with the rest of our health care team.”
Mr. Peaker joins Cowen from Oppenheimer & Co., where he spent over three years as a senior research analyst covering the biotechnology sector. He previously held biotechnology equity research positions at Rodman & Renshaw and at Cowen and Company. Mr. Peaker holds Bachelor of Science degrees in Physics and in Chemistry, summa cum laude, from State University of New York at Stony Brook, and a Ph.D. in Biophysics from Stanford University. He is a CFA® charterholder.
About Cowen Group, Inc.
Cowen Group, Inc. is a diversified financial services firm and, together with its consolidated subsidiaries, provides alternative asset management, investment banking, research, and sales and trading services through its two business segments: Ramius and its affiliates make up the Company’s alternative investment segment, while Cowen and Company and its affiliates make up the Company’s broker-dealer segment. Ramius provides alternative asset management solutions to a global client base and manages a significant portion of Cowen’s proprietary capital. Cowen and Company and its affiliates offer industry focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Founded in 1918, the firm is headquartered in New York and has offices worldwide.
